You are here

semaglutide

FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application

FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application

Benzinga

Flag link:

Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture

Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture

Fierce Biotech

type 2 diabetes

clinical trials

Flag link:

Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss

Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss

Endpoints

Flag link:

Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

Yahoo/Global Newswire

type 2 diabetes

Flag link:

Gilead and Novo plot next steps after trial data from NASH combo

Gilead and Novo plot next steps after trial data from NASH combo

Pharmaforum

Gilead Sciences

clinical trials

Flag link:

Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow

Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow

Endpoints

breakthrough therapy

Flag link:

Novo adds weight to its obesity goals

Novo adds weight to its obesity goals

EP Vantage

Flag link:

Novo launches type 2 diabetes pill in UK after NICE waives review

Novo launches type 2 diabetes pill in UK after NICE waives review

Pharmaforum

type 2 diabetes

Flag link:

Novo Nordisk axes experimental obesity drugs after success with later-stage meds

Novo Nordisk axes experimental obesity drugs after success with later-stage meds

Fierce Biotech

Flag link:

Novo's diabetes drug also appears to work in NASH

Novo's diabetes drug also appears to work in NASH

BioPharma Dive

Flag link:

Mark Your Calendar For These September PDUFA Dates

Mark Your Calendar For These September PDUFA Dates

Yahoo/Benzinga

Xeris Pharmaceuticals

Flag link:

ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?

ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?

Fierce Pharma

Flag link:

Novo Nordisk seeks FDA nod for oral diabetes pill

Novo Nordisk seeks FDA nod for oral diabetes pill

Drug Delivery Business News

Flag link:

Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?

Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?

Fierce Pharma

Teva Pharmaceutical

Flag link:

Novo bets on swift FDA review for oral diabetes drug semaglutide

Novo bets on swift FDA review for oral diabetes drug semaglutide

Endpoints

Flag link:

The 20 Hottest Pipeline Drugs to Watch in 2019

The 20 Hottest Pipeline Drugs to Watch in 2019

BioSpace

VX-659 + tezacaftor + ivacaftor

valoctocogene roxaparvovec

Flag link:

3 Biotechs With Potential Blockbusters Near the Finish Line

3 Biotechs With Potential Blockbusters Near the Finish Line

Motley Fool

Vertex Pharmaceuticals

VX-659 + tezacaftor + ivacaftor

Flag link:

Novo Nordisk’s Semaglutide Hits Mark in Type 2 Diabetes Trial

Novo Nordisk’s Semaglutide Hits Mark in Type 2 Diabetes Trial

BioSpace

clinical trials

type 2 diabetes

Flag link:

Novo Nordisk trumpets more Januvia-topping data for oral semaglutide

Novo Nordisk trumpets more Januvia-topping data for oral semaglutide

Fierce Pharma

Flag link:

Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia

Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia

Fierce Pharma

Flag link:

Pages